Brello Rise enters the obesity care landscape as a digital wellness adjunct to medical weight loss
Brello Health launches Brello Rise, a digital studio for patients in medical weight loss programs. Find out what this signals for obesity care models.
Pharma & Biotech
Pharma & Biotech
Why BioCryst’s Astria acquisition reshapes long-acting competition in hereditary angioedema prophylaxis
BioCryst completes its Astria acquisition to expand long-acting hereditary angioedema leadership. Find out what this means for HAE treatment competition.
Pharma & Biotech
How urcosimod’s FDA compassionate use authorization reshapes development risk in ocular neuropathic pain
FDA allows compassionate use of urcosimod for neuropathic corneal pain. Read how this decision reshapes regulatory, clinical, and development risk.
Medical Devices & Diagnostics
What makes Break Wave different? SonoMotion’s FDA clearance puts ultrasound lithotripsy in the spotlight
SonoMotion’s Break Wave lithotripsy device wins FDA clearance for non-invasive kidney stone treatment. Find out what this changes for urology practices.
Pharma & Biotech
How Brazil’s GMP approval for pembrolizumab biosimilar changes global biosimilar dynamics
Blau Farmacêutica’s pembrolizumab biosimilar earns ANVISA GMP approval—see what this means for Brazil’s global position in cancer immunotherapy.
Pharma & Biotech
Thailand approves NERLYNX for HER2+ breast cancer: Will it change relapse prevention?
NERLYNX launches in Thailand for HER2+ breast cancer. Find out how neratinib could reshape relapse prevention and treatment sequencing across Southeast Asia.
Pharma & Biotech
Can Hoth Therapeutics’s topical HT-001 redefine EGFR therapy adherence in cancer supportive care?
Hoth’s HT-001 showed 100% response in EGFR therapy toxicity trial. Learn what this means for cancer symptom relief, treatment continuity, and future trials.
Pharma & Biotech
PAQ Therapeutics initiates Phase 1 for PT0511 pan-KRAS degrader, raises $77m in Series B
PAQ Therapeutics begins Phase 1 trial for PT0511 pan-KRAS degrader and raises $77M. Find out what this means for the future of KRAS-targeted cancer therapy.
Pharma & Biotech
Can Mabwell’s ADC 7MW4911 overcome drug resistance in late-stage GI cancers?
Mabwell begins U.S. trial of novel CDH17-targeting ADC 7MW4911 for resistant GI cancers. Learn what makes this payload and target combination clinically unique.
Pharma & Biotech
AI in clinical operations: Can PhaseV’s real-time site optimization reshape IBD trial efficiency?
Find out how PhaseV’s AI-powered ClinOps Optimizer is changing IBD trial site selection with causal ML and real-time analytics. Read the full analysis.